COVID-19 Still Surging in 2026: Data, Seasonal Oscillation, and Booster Guidance

Rising Cases in 2026

Many assume COVID‑19 has ended, but the Chinese CDC’s June 2026 report recorded 79,000 new confirmed cases, 130 severe cases, and a single death, indicating an overall upward trend.

Current Epidemiological Data

Sentinel hospital positivity climbed from 2.9% to 6.4% over weeks 23‑26, and the dominant variant was Omicron sub‑lineage NB.1.8.1, accounting for over 96% of infections. WHO’s May 2025 risk assessment classified NB.1.8.1 as “low” risk; its mutations (A435S, T478I) increase ACE2 binding, making it more transmissible but not more severe, which aligns with the observed low death and severe‑case rates.

Why the Rise Is Predictable

The increase resembles a seasonal oscillation rather than a new crisis. A simple SIRS model with immunity waning explains the pattern: the population is divided into susceptible, infected, and recovered groups, with recovered individuals returning to susceptibility as antibodies decay and variants escape immunity. If immunity were lifelong, the epidemic would burn out; with waning immunity, the system exhibits damped oscillations, producing successive waves.

Evidence from Research

A 2026 PLOS Pathogens study using real‑world data confirmed that rapid short‑term immunity decay alone can generate a yearly COVID‑19 cycle, without invoking multiple strain assumptions. In warm climates, this manifests as a small peak every 3–4 months.

Assessing Booster Benefits

Protection consists of two layers. First, antibody titers decay exponentially; after two doses the half‑life is 56–66 days, extending to 76–102 days after a booster, while hybrid immunity (vaccination + infection) can last over 200 days. The escape factor for NB.1.8.1 is about 1.5.

Second, the relationship between neutralizing titer and protection follows an S‑shaped curve (Khoury et al., Nature Medicine 2021). Fifty percent protection against infection requires 20% of convalescent titer, whereas the same protection against severe disease needs only 3%.

Projected Protection Over Time

Months since last immunity | Effective titer | Infection protection | Severe‑disease protection
0  | 1.33 | ~92% | ~99%
3  | 0.67 | ~83% | ~98%
6  | 0.33 | ~66% | ~96%
9  | 0.17 | ~45% | ~88%
12 | 0.08 | ~24% | ~79%

Real‑world VISION data from the United States matches this trend: infection protection falls to roughly 45% by nine months, while severe‑disease protection remains around 80% after a year, though it declines faster in the elderly.

Targeted Recommendations

For young, healthy individuals, the primary concern is the rapidly declining infection‑protection curve; boosters offer a short‑lived benefit, making strong innate immunity and temporary protection more important.

For older adults, people with comorbidities, or immunocompromised patients, the durable severe‑disease protection curve is critical; boosters provide clear net benefit.

Individuals with high exposure risk (e.g., caregivers, participants in large indoor events, households with vulnerable members) should consider receiving a booster one to two months before exposure to raise the infection‑protection curve.

Supply Constraints and Variant Updates

In mainland China, vaccination strategies have not yet shifted to the JN.1 lineage, and most sites require out‑of‑pocket payment with limited supply. Hong Kong introduced a JN.1 mRNA vaccine in November 2024, covering those over six months old. A 2024 Nature paper by Cao Yun‑long’s team demonstrated the necessity of updating boosters to JN.1 because circulating strains have moved from XBB to JN.1 and its descendants, while many marketed vaccines still target older lineages.

Practical Guidance

If a JN.1‑matched vaccine is available and the person is high‑risk, it should be administered. If only older‑lineage vaccines are accessible, they still confer substantial protection against severe disease but little against infection. When no vaccine is obtainable, non‑pharmaceutical measures—masking, ventilation, hand hygiene—remain essential.

Coexistence Without Forgetting

Equating COVID‑19 to a “big flu” is dangerous; evidence shows it causes greater multi‑organ damage, immune depletion, and long‑COVID sequelae than seasonal influenza. Recognizing its low‑level, cyclical presence while accounting for its long‑term health burden is crucial.

Global Perspective

Variants such as NB.1.8.1’s descendant PQ.16.1.1 have spread to neighboring countries (Thailand, Singapore, the United States), illustrating how surveillance or vaccine gaps in one region become global risks. International sharing of viral genomes and coordinated vaccine development were key to suppressing the pandemic and remain vital.